Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Update

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the target of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 736,300 shares, a growth of 462.1% from the January 31st total of 131,000 shares. Based on an average daily trading volume, of 1,410,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 5.9% of the company’s shares are short sold.

Hedge Funds Weigh In On Cyclo Therapeutics

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Two Sigma Securities LLC bought a new stake in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 42,541 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned about 0.15% of Cyclo Therapeutics as of its most recent filing with the SEC. 68.55% of the stock is owned by institutional investors.

Cyclo Therapeutics Trading Down 2.0 %

Shares of NASDAQ CYTH traded down $0.02 during mid-day trading on Friday, reaching $0.76. 26,744 shares of the company’s stock were exchanged, compared to its average volume of 2,327,837. Cyclo Therapeutics has a twelve month low of $0.55 and a twelve month high of $1.79. The firm has a market capitalization of $24.85 million, a price-to-earnings ratio of -0.84 and a beta of -0.49. The business has a fifty day simple moving average of $0.77 and a 200 day simple moving average of $0.76.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.